Demand for COVID Vaccines Expected to Get Heated â And Fast
With two vaccines against coronavirus disease poised for release within weeks, experts say they expect attitudes to shift dramatically from hesitancy to âBeanie Babyâ-level urgency.
The independent source for health policy research, polling, and news.
701 - 720 of 818 Results
With two vaccines against coronavirus disease poised for release within weeks, experts say they expect attitudes to shift dramatically from hesitancy to âBeanie Babyâ-level urgency.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Hereâs a collection of their appearances.
The official transition to a Joe Biden administration has finally begun, and he is expected to announce his health care team soon, including a new secretary of Health and Human Services. Meanwhile, as the COVID-19 pandemic worsens in the U.S., officials are preparing for the effort to get Americans vaccinated as soon as vaccines are approved by the FDA. Alice Miranda Ollstein of Politico, Margot Sanger-Katz of The New York Times and Paige Winfield Cunningham of The Washington Post join KHNâs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHNâs Julie Appleby, who wrote the latest KHN-NPR âBill of the Monthâ installment.
Fears over COVID-19 have contributed to a slump in inoculations among children. Now the federal government is looking to pharmacists for help, but many of them do not participate in a program that offers free shots to half the kids in the U.S.
Dentists and optometrists across the country are trying to join in the fight to get everyone vaccinated against COVID-19, the flu and other diseases.
A Trump administration maneuver allows executives who are leading the federal effort to keep investments in drug companies that would benefit from the pandemic response.
Drugmakers will walk away with massive profits, but much of the pioneering work on mRNA vaccines was done with government money.
Former Vice President Joe Biden is now the president-elect nearly everywhere but inside the Trump administration, where the president refuses to concede and has ordered officials not to begin a formal transition. That is a particular problem for health care as the COVID-19 pandemic surges. Meanwhile, thereâs good news on the vaccine front, but itâs unlikely one will arrive by winter. And the ACA was back before the Supreme Court â again. Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Shefali Luthra of the 19th News join KHNâs Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
From the likelihood of achy, flu-like side effects to the need for two doses, weeks apart, consumers need to know now what to expect when vaccines to prevent COVID-19 roll out.
The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit.
It typically takes months to install new leadership, but with COVID deaths set to surge through the winter, many Democrats say Biden doesnât have that sort of time.
The Department of Veterans Affairs hopes to enroll 8,000 people in advanced-stage trials of four leading vaccine candidates. The Defense Department earlier announced plans to enlist 3,000 volunteers in trials.
Former President Barack Obama says President Donald Trump is âjealous of COVIDâs media coverage.â Indeed, Trump has complained at his rallies, attended by mostly maskless supporters, about how the media covers the pandemic â at a time when cases are rising rapidly across the nation. Meanwhile, open enrollment is about to begin for the Affordable Care Act in a year when many people need coverage, but the lawâs future is not secure. Joanne Kenen of Politico, Tami Luhby of CNN and Anna Edney of Bloomberg News join KHNâs Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHNâs Anna Almendrala about the latest KHN-NPR âBill of the Monthâ installment.
Some argue that vaccines capable of preventing any COVID-19 symptoms should qualify for widespread use, but others want much larger trials to prove the vaccines can reduce hospitalizations or deaths.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Hereâs a collection of their appearances.
To stop the coronavirus, we need to stop super-spreader events.
President Donald Trump is one of at least two dozen people tied to the White House who have tested positive for COVID-19. Negotiations on the next round of COVID relief are off again â maybe. And the FDA and CDC continue to fight for scientific credibility. Alice Miranda Ollstein of Politico, Kimberly Leonard of Business Insider and Erin Mershon of Stat News join KHNâs Julie Rovner to discuss these issues and more. Plus, Rovner interviews Amy Howe of SCOTUSblog about what the Supreme Court might do with the latest case challenging the constitutionality of the Affordable Care Act.
During this, the first and only vice presidential debate of the 2020 election season, the two candidates clashed over the coronavirus and other health care issues, as well as a range of other topics.
California and at least five other states have said they may independently vet any vaccines. Experts warn that could needlessly confuse the public.
Approval of a vaccine will be an important step in defeating COVID-19. But it wonât immediately end the pandemic.
Š 2026 KFF